Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

November 25, 2014
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.

November 13, 2014
Bioniche Life Sciences Inc. Announces Results of Annual General Meeting of Shareholders SHAREHOLDERS

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

Corporate

November 2014

25/11/14
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.

13/11/14
Bioniche Life Sciences Inc. Announces Results of Annual General Meeting of Shareholders SHAREHOLDERS

06/11/14
Orphan Drug Designation Update and Annual General Meeting Reminder

August 2014

21/08/14
Bioniche Life Sciences Announces Overnight Marketed Offering

June 2014

13/06/14
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference

03/06/14
Bioniche Provides Corporate Update

April 2014

15/04/14
Vétoquinol and Bioniche Life Sciences Inc. Close Sale of Bioniche Animal Health Business

14/04/14
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business

03/04/14
ISS Recommends that Bioniche Shareholders Vote in Favour of Animal Health Sale Transaction

03/04/14
Bioniche Life Sciences Inc. Continues to Execute on Strategic Review

March 2014

13/03/14
Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast

04/03/14
Bioniche Life Sciences Inc. Announces Key Corporate Updates

January 2014

07/01/14
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer

November 2013

04/11/13
Bioniche Life Sciences Inc. Announces the Appointment of a New Chief Executive Officer

October 2013

07/10/13
Bioniche Provides an Update on Plans for a New Drug Submission Filing in Canada

September 2013

11/09/13
Bioniche Founder and CEO Announces his New Role with the Company

July 2013

23/07/13
Ontario Court Confirms Timing of Bioniche’s Annual Meeting of Shareholders

05/07/13
Paladin Labs Inc. and Bioniche Life Sciences Inc. Officially Close Debt Refinancing and Urocidin™ Licensing Deals

June 2013

27/06/13
Bioniche Life Sciences Inc. to Provide an Update on Vaccine Manufacturing Centre Validation

12/06/13
Bioniche Founder and CEO Addresses Shareholders

May 2013

29/05/13
Bioniche Responds to Dissident Shareholders and Rejects Call for Early Shareholder Meeting

April 2013

22/04/13
Bioniche Life Sciences Inc. Responds to Letter from Former Biovail Executives

January 2013

30/01/13
Bioniche Life Sciences Inc. Terminates its License Agreement with Trophogen Inc.

December 2012

06/12/12
Bioniche Life Sciences Inc. Announces a Change to its Board of Directors

July 2012

30/07/12
Bioniche Life Sciences Inc. Appoints an Independent Chairman of its Board of Directors

November 2011

09/11/11
Bioniche Life Sciences Inc. Holds Annual & Special Meeting of Shareholders

October 2011

20/10/11
New York Court Grants Summary Judgment in Favour of Bioniche Life Sciences Inc.

September 2011

29/09/11
Bioniche Life Sciences Inc. Launches Three New Products

August 2011

01/08/11
Bioniche Life Sciences Inc. Will Not Proceed With Business and Asset Acquisition of Plasvacc Holdings Limited

July 2011

04/07/11
Bioniche Life Sciences Inc. has Agreed to Acquire Plasvacc Holdings Limited of Australia

March 2011

31/03/11
Folltropin®-V - a Key Bioniche Animal Health Product - Receives Marketing Authorization in China

January 2011

03/01/11
Bioniche Announces Reorganization of Leadership Team

December 2010

21/12/10
Bioniche Animal Health and IMV Technologies Sign European Distribution Agreement

06/12/10
Bioniche, Through Distributor, Provides Exclusive Supply to Angus Association in Australia

October 2010

28/10/10
Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada for a Second Time

August 2010

25/08/10
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

June 2010

17/06/10
Bioniche Strengthens its International Patent Portfolio for its MCC & Oligonucleotide Technology Platforms

April 2010

19/04/10
Bioniche Receives FedDev Ontario Investment to Support Fermentation Scale-Up for New Vaccine Manufacturing Centre

August 2009

05/08/09
Bioniche Announces Resignation of its CFO

June 2009

22/06/09
Bioniche Provides a Corporate Update

April 2009

27/04/09
Bioniche Provides a Corporate Update

May 2008

23/05/08
Bioniche Presents Pre-Clinical Research at Two International Conferences

April 2008

18/04/08
Bioniche Reports the Passing of its Board Chair

February 2008

08/02/08
Bioniche Receives $5 Million Capital Financing Support to Scale-up E. coli O157:H7 Vaccine Production

December 2007

20/12/07
Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario

18/12/07
Bioniche Receives $10 Million of Provincial Government Support to Scale-up Vaccine Production in Ontario

17/12/07
Announcement Planned by Ontario Ministry of Economic Development and Trade

04/12/07
Bioniche Recognized as One of the Top 10 Life Science Companies in Canada

November 2007

15/11/07
Bioniche Presents at Annual Convention of Canadian Association of Fairs & Exhibitions

06/11/07
Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference

October 2007

05/10/07
Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial

04/10/07
Bioniche to Present at BioContact Quebec 2007

September 2007

10/09/07
Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial

July 2007

19/07/07
Bioniche Appoints New Animal Health and Food Safety Leadership Team

18/07/07
Bioniche Appoints New Director to its Board

May 2007

01/05/07
Bioniche E. coli O157:H7 Vaccine Discussed at 4th International Conference on Vaccines for Enteric Diseases

March 2007

30/03/07
Bioniche Recognized with Québec Biotechnology Award

29/03/07
Bioniche and Technology Partnerships Canada Amend Agreement on MCC Research Project

02/03/07
Bioniche Files Final Short-Form Prospectus for Offering of Units

February 2007

09/02/07
Bioniche Files Preliminary Short-Form Prospectus for Offering of Units

January 2007

12/01/07
Bioniche Further Pays Down Debt with Laurus Master Funds

December 2006

22/12/06
Bioniche Further Pays Down Debt

08/12/06
Bioniche Completes Sale of Two Remaining Assets Associated with Irish Pharma Group

November 2006

07/11/06
Bioniche Plans to Liquidate Two Remaining Assets Associated with Irish Pharma Group

October 2006

31/10/06
Bioniche to Present at Rodman & Renshaw 8th Annual Healthcare Conference

02/10/06
Bioniche Board Approves a Shareholders Rights Plan

September 2006

29/09/06
Bioniche Life Sciences Inc. Re-Files its 2005 MD&A and Certificates

June 2006

27/06/06
Cameron Groome Joins Bioniche as Executive Vice-President, Corporate & Strategic Development

March 2006

22/03/06
Updates on MCC Phase III Bladder Cancer Study and E. coli O157:H7 Cattle Vaccine Regulatory Progress

February 2006

01/02/06
Bioniche and RoundTable Healthcare Partners Close Sale of Bioniche Pharma Group Ltd.

January 2006

12/01/06
Bioniche Signs Definitive Purchase Agreement for Sale of Pharma Group to RoundTable Healthcare Partners

October 2005

28/10/05
Bioniche Clarifies Terms of Pharma Group Sale and Private Placement

18/10/05
Bioniche Pharma Group and AngioDynamics Sign Exclusive Distribution Agreement for Sotradecol(R) Injection

05/10/05
Bioniche and ICC Private Equity Fund Agree to Sell Bioniche Pharma Group to RoundTable Healthcare Partners

04/10/05
Bioniche Retains Blackmont Capital to Assist in the Sale of its Pharma Business Unit

September 2005

26/09/05
Bioniche in Good Standing with Technology Partnerships Canada (TPC)

July 2005

12/07/05
Bioniche Reports Positive News from BetacTM Product Recall Investigation

June 2005

20/06/05
Bioniche Life Sciences Retains GCI Group as Strategic Investor Relations Counsel

13/06/05
Bioniche Appoints New Chief Medical Officer to Advance Clinical Trials

01/06/05
Bioniche Pharma Group and Grünenthal Sign Exclusive Agreement for Distribution of Suplasyn®

May 2005

17/05/05
Bioniche Granted Additional Patent for Mycobacterial Cell Wall Technology

13/05/05
Bioniche Announces Change in Board of Directors Composition

04/05/05
Bioniche to Present at Rodman & Renshaw

March 2005

29/03/05
Bioniche Granted European Patent for MCC in Bladder Cancer

22/03/05
Bioniche Presents Further Data on Mycobacterial Cell Wall-DNA Complex (MCC) at European Association of Urology 20th Congress

December 2004

23/12/04
Bioniche Animal Health Appoints New Leaders of European and Australian/Asian Operations

06/12/04
Senior Personnel Change at Bioniche

November 2004

18/11/04
New Data Confirms Unique Anticancer Activity Profile

08/11/04
New Studies Demonstrate Anti-Cancer Activity of Bioniche Technology Against Canine Cancer

04/11/04
Bioniche Reports First Quarter Results for Fiscal 2005

October 2004

06/10/04
Bioniche Expands its Intellectual Property Portfolio

September 2004

23/09/04
Bioniche Presents Data on Cystistat and Launches Product Web Site at Inaugural Multinational Interstitial Cystitis Association Annual Meeting

20/09/04
Bioniche Appoints a Chief Operating Officer

August 2004

26/08/04
Bioniche Ranked Among the Top 100 Global Biotechnology Companies by Med Ad News

June 2004

14/06/04
Bioniche Serves Community Needs Through New Pet Loss Program

08/06/04
Bioniche Ranked Among Canada’s Top 100 Fastest-Growing Companies by PROFIT Magazine

01/06/04
Bioniche Retains The Anne McBride Company Inc.


Newsroom

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy